One question with regard to partering,
I am thinking for big pharma what would be the more reasonable choice for a partnering scenario
1. partnering for DMD. It seems big pharma would take much less risk
2. partnering for any new indication. This seems much more risky for any big pharma player
3. Or does some company just buy in everything?
At the current stage of the company does anyone have similar experiences?
I hope any of the two outcomes will happen...
Have a good day.
One question with regard to partering,I am thinking for big...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |